Compare Adaptive Biotechnologies Corp (ADPT) vs Eaton Corporation plc (ETN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Eaton Corporation plc — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Eaton Corporation plc trades at $464.31 (market cap $172.82B). The key difference: Eaton Corporation plc is far larger — about 42.8× Adaptive Biotechnologies Corp's market cap, and Eaton Corporation plc pays a 0.99% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | ETN | |
|---|---|---|
Market Cap | $4.04B | $172.82B |
Sector | Health | Technology |
52-Week High | $25.45 | $459.29 |
52-Week Low | $12.30 | $315.82 |
Enterprise Value | $4.10B | $193.45B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Eaton Corporation (ETN) trades at $468.37, up 5.26% in 24 hours, reflecting strong momentum after recent earnings beats. The stock exhibits a bullish technical trend with support at $456 and resistance at $470. Q2 2026 earnings beat expectations with EPS of $3.15 versus $3.07 estimated, and the company raised its full-year outlook, driven by robust demand in electrical and data center segments.
Outlook remains positive given raised guidance and AI-driven power infrastructure demand, but risks include premium valuation (P/E 45.31) and execution challenges. Analyst consensus is bullish with a $499.75 price target, though investors should monitor competitive pressures and macroeconomic conditions affecting industrial spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Eaton Corporation plc
Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.
Read more on ETN →
